Men’s Health Month each June draws attention to a well-documented disparity in care-seeking behavior. Men are less likely than women to engage in routine preventive care, more likely to defer evaluation of symptoms, and consequently more likely to present with advanced disease. The clinical and financial consequences of that pattern are considerable.
Prostate cancer illustrates the point. It is the most frequently diagnosed malignancy among American men apart from skin cancer, and the American Cancer Society projects approximately 333,830 new diagnoses and 36,320 deaths in 2026. Roughly one in eight men will be diagnosed during his lifetime, the disease accounts for nearly one-third of all male cancer diagnoses, and it remains the second-leading cause of cancer death among men. More than 3.5 million men in the United States are living following a prostate cancer diagnosis. Significant disparities persist: Black men are diagnosed at approximately 1.7 times the rate of White men and die at roughly twice the rate.
Prostate cancer is only one component of the broader men’s health burden. Benign prostatic hyperplasia (BPH) affects approximately half of men by their fifties and the substantial majority by their eighties. Urolithiasis, urinary tract infection, erectile dysfunction, male infertility, and incontinence collectively affect a large share of the male population over the course of a lifetime. The encouraging counterpoint is that prostate cancer detected at an early, localized stage carries a five-year relative survival rate exceeding 99 percent — underscoring the value of timely evaluation and accurate diagnosis.
The Urologist’s Role Across the Continuum of Care
Urology, the specialty dedicated to the urinary tract and the male reproductive system, occupies a central position in nearly every dimension of men’s health. The urologist’s responsibilities span the full arc of care:
- Screening and risk assessment — interpreting PSA results, performing examinations, and counseling patients on the appropriateness and timing of further workup.
- Diagnosis — ordering and performing imaging, cystoscopy, and the prostate biopsies that confirm or exclude malignancy.
- Treatment — managing BPH, addressing urolithiasis, performing prostatectomy and other oncologic procedures, and treating incontinence, infertility, and sexual dysfunction.
- Survivorship and chronic disease management — providing longitudinal follow-up, monitoring for recurrence, and managing the long-term sequelae of treatment.
Because the urologist frequently serves as the single specialist a patient sees across screening, diagnosis, surgery, and follow-up, the specialty is foundational to men’s health. That same continuity makes accurate coding a direct determinant of whether a practice can continue to deliver this care on a sustainable basis.
Why the 2026 Code Set Warrants Immediate Attention
The CPT code set was revised effective January 1, 2026, and the changes affecting urology are among the most substantial in recent years. Notably, the most significant revisions apply to core men’s health procedures — prostate biopsy, BPH treatment, and radical prostatectomy. Because these are high-volume and frequently high-dollar services tied directly to cancer diagnosis and treatment, coding errors carry meaningful consequences: claim denials, administrative rework, delayed reimbursement, and compliance exposure on the procedures that define the practice.
Practices still operating from 2025 favorites lists, charge tickets, and electronic health record templates should prioritize the following changes.
Restructured Prostate Biopsy Coding (55707–55715)
The most consequential change is the deletion of code 55700, the longstanding single code for prostate needle biopsy. Effective January 1, 2026, it is no longer valid and will generate an immediate invalid-code rejection.
It has been replaced by a structured family of codes, 55707 through 55715, designed to reflect contemporary biopsy practice. The new set distinguishes services by approach (transrectal versus transperineal), technique (systematic versus targeted sampling), and guidance method (ultrasound, MRI–ultrasound software fusion, or in-bore CT/MRI). Imaging guidance is now bundled into the biopsy codes rather than reported separately.
The structure may be summarized as follows. Practices should confirm the precise official descriptor in the current CPT manual before billing.
- 55707 — Transrectal approach, ultrasound-guided, systematic sampling.
- 55708 — Transrectal, ultrasound-guided systematic sampling with MRI-fusion targeting of the first targeted lesion.
- 55709 — Transperineal approach, ultrasound-guided, systematic sampling.
- 55710 — Transperineal, ultrasound-guided systematic sampling with MRI-fusion targeting of the first targeted lesion.
- 55711 — Transrectal, MRI–ultrasound fusion, targeted lesion(s) only, first targeted lesion.
- 55712 — Transperineal, MRI–ultrasound fusion, targeted lesion(s) only, first targeted lesion.
- 55713 — In-bore CT- or MRI-guided, systematic and targeted, first targeted lesion.
- 55714 — In-bore CT- or MRI-guided, targeted lesion(s) only, first targeted lesion.
- 55715 — Add-on code for each additional MRI-fusion or in-bore targeted lesion beyond the first, reported in conjunction with the primary biopsy code.
Documentation and Reimbursement Considerations for Biopsy Coding
Code selection alone does not ensure clean claims. Several pairing and documentation requirements represent common sources of denial:
- Cognitive fusion is distinct from software-based MRI fusion. When the provider correlates the MRI with live ultrasound mentally (cognitive fusion) rather than employing a software fusion platform, the service is reported as ultrasound/systematic — not as an MRI-fusion code. The fusion codes (including 55710, 55712, and the 55715 add-on) require an actual software image-fusion platform, and the operative note must document its use explicitly.
- The 55715 add-on carries specific conditions. It applies to each targeted lesion beyond the first, and each such lesion must have been identified on the MRI for targeted sampling. A lesion identified only on intra-procedure ultrasound does not qualify.
- Incompatible code pairings must be avoided. A targeted-only code, such as 55712 (transperineal fusion without systematic sampling), should not be reported together with a systematic-plus-targeted code, such as 55710, for the same session.
- Post-MRI image processing may be separately reportable. Three-dimensional image processing and segmentation of the prostate (76376/76377) may be billed separately when not otherwise captured; verify that another provider has not already reported it.
In summary, documentation must now clearly establish the approach, whether sampling was systematic or targeted, whether software fusion was employed, and the number of lesions targeted. Operative notes that do not support these distinctions place the corresponding claims at risk.
Expanded Laparoscopic Radical Prostatectomy Code Family
Radical prostatectomy coding has also been expanded. Previously, code 55866 (laparoscopic, including robotic-assisted, radical prostatectomy) functioned as a single code, with any pelvic lymph node dissection reported separately. For 2026, lymph node dissection is incorporated into a three-code family:
- 55866 (revised) — Laparoscopic radical prostatectomy without lymph node dissection.
- 55868 (new) — The same procedure with limited pelvic lymph node biopsy or dissection.
- 55869 (new) — The same procedure with bilateral pelvic lymphadenectomy, including the external iliac, hypogastric, and obturator nodes.
The AMA resequenced these codes so that the related procedures group together by degree of complexity. The practical implication is that coders should no longer default to 55866 and append a separate node-dissection code; documentation must determine which of the three codes applies, and prior practices of unbundling node dissection will now produce errors.
Reclassification of Aquablation to a Category I Code
Aquablation — transurethral robotic-assisted waterjet resection of the prostate for BPH — has transitioned from the temporary Category III system to a permanent Category I code. The former 0421T has been replaced by 52597. Practices continuing to report 0421T will encounter denials and should confirm that the change is reflected in charge capture and applicable payer policies.
Additional New and Revised Codes
The 2026 update affected several additional areas relevant to urology:
- New BPH and prostate procedure codes were added to the vesical neck and prostate set, including reporting for irreversible electroporation of the prostate and cystourethroscopy with balloon dilation and drug delivery for BPH.
- 0988T and 0989T — integrated tibial nerve stimulator services for overactive bladder and urinary urgency.
- 0991T — low-energy ureteral lithotripsy.
- 1000T — administration of autologous muscle progenitor cell therapy.
- New shorter-duration remote physiologic monitoring (RPM) codes permitting reporting of monitoring windows of approximately 2 to 15 days within a 30-day period, billable once per month.
Reimbursement Context: The 2026 Conversion Factor
For the first time in several years, the Medicare conversion factor increased, and 2026 introduced two distinct conversion factors: one for clinicians participating in a qualified Alternative Payment Model (APM) and one for all others. The APM conversion factor has been reported at approximately $33.57 (an increase of roughly 3.77 percent) and the non-APM factor at approximately $33.40 (an increase of roughly 3.26 percent).
Practice leadership should note, however, that despite the headline increase, the overall estimated impact on urology for 2026 is approximately zero percent once budget-neutrality adjustments and shifts in relative value units are accounted for. Against rising costs for staffing, facilities, and supplies, the net effect is effectively flat. Consequently, disciplined coding and denial prevention — rather than rate increases — represent the practical means of protecting margin in 2026.
Recommended Action Items for Practice Teams
- Retire code 55700 across all systems. Remove it from favorites lists, superbills, charge tickets, and EHR templates, and map staff to the 55707–55715 family.
- Train staff on the biopsy coding logic. Approach, systematic versus targeted technique, cognitive versus software fusion, and lesion count each affect code selection; a quick-reference grid for providers and coders is advisable.
- Strengthen biopsy documentation. For any fusion code, require that the note identify the software fusion platform and each MRI-identified targeted lesion.
- Re-educate teams on the prostatectomy family. Discontinue unbundling of node dissection and select 55866, 55868, or 55869 according to documentation.
- Confirm the Aquablation transition. Code 0421T is retired; 52597 applies for 2026 claims.
- Conduct a focused claims audit. Review a sample of post-January biopsy, BPH, and prostatectomy claims to verify that the new codes are applied and supported; early identification of error patterns is substantially less costly than reworking a quarter of denials.
- Maintain modifier discipline. Same-day E/M reported with a procedure (modifier -25) and distinct procedural services (modifier -59) remain among the most frequent urology denial triggers and are unaffected by the new codes.
Conclusion
The concentration of the 2026 urology changes around prostate procedures reflects the clinical reality that prostate care drives a large share of urologic practice. As awareness initiatives encourage more men to pursue screening and early detection, biopsy and treatment volumes can be expected to rise accordingly. Accurate coding of these services is not merely an administrative function; it sustains the financial viability of men’s health services and helps ensure that care proceeds without interruption. A correctly adjudicated claim ultimately represents one fewer barrier between a patient and the diagnosis or treatment that may extend his life.
CPT is a registered trademark of the American Medical Association. This article is provided for general informational purposes only and does not constitute coding, billing, legal, or financial advice. Code numbers and descriptions are summarized in plain language; practices should consult the official CPT manual and the current CMS Medicare Physician Fee Schedule final rule for complete descriptors, bundling and NCCI edits, and payer-specific guidance before billing. Statistics and conversion-factor figures are drawn from publicly reported 2026 sources and are approximate and subject to revision.